Activated leukocyte cell adhesion molecule (CD166): An "inert" cancer stem cell marker for non-small cell lung cancer?

Stem Cells

Volumn 32, Issue 6, 2014, Pages 1429-1436

  Tachezy, Michael ^a   Zander, Hilke ^a   Wolters Eisfeld, Gerrit ^a   Müller, Julia ^a   Wicklein, Daniel ^a   Gebauer, Florian ^a   Izbicki, Jakob R ^a   Bockhorn, Maximilian ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Activated leukocyte cell adhesion molecule; Biomarker; Cancer stem cell; CD166; Non small cell lung cancer; Prognosis; Tumor initiating cells

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ALCAM PROTEIN, HUMAN; FETOPROTEIN; LEUKOCYTE ANTIGEN; NERVE CELL ADHESION MOLECULE; TUMOR MARKER;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SIZE; CANCER STEM CELL; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; TISSUE MICROARRAY; AGED; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION MOLECULES, NEURONAL; CELL LINE, TUMOR; FEMALE; FETAL PROTEINS; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASTIC STEM CELLS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84901414125     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1665     Document Type: Article

References (32)

1. Kitamura H, Okudela K, Yazawa T, et al. Cancer stem cell: Implications in cancer biology and therapy with special reference to lung cancer. Lung Cancer 2009; 66: 275-281.
2. Eramo A, Haas TL, De Maria R,. Lung cancer stem cells: Tools and targets to fight lung cancer. Oncogene 2010; 29: 4625-4635.
3. Pardal R, Clarke MF, Morrison SJ,. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003; 3: 895-902.
4. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
5. Welte Y, Adjaye J, Lehrach HR, et al. Cancer stem cells in solid tumors: Elusive or illusive? Cell Commun Signal 2010; 8: 6.
6. Zhang WC, Shyh-Chang N, Yang H, et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 2012; 148: 259-272.
7. Masedunskas A, King JA, Tan F, et al. Activated leukocyte cell adhesion molecule is a component of the endothelial junction involved in transendothelial monocyte migration. FEBS Lett 2006; 580: 2637-2645.
8. King JA, Tan F, Mbeunkui F, et al. Mechanisms of transcriptional regulation and prognostic significance of activated leukocyte cell adhesion molecule in cancer. Mol Cancer 2010; 9: 266.
9. Weidle UH, Eggle D, Klostermann S, et al. ALCAM/CD166: Cancer-related issues. Cancer Genomics Proteomics 2010; 7: 231-243.
10. van Kilsdonk JW, Wilting RH, Bergers M, et al. Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule. Cancer Res 2008; 68: 3671-3679.
11. Ofori-Acquah SF, King JA,. Activated leukocyte cell adhesion molecule: A new paradox in cancer. Transl Res 2008; 151: 122-128.
12. Ihnen M, Muller V, Wirtz RM, et al. Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat 2008; 112: 419-427.
13. Mezzanzanica D, Fabbi M, Bagnoli M, et al. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res 2008; 14: 1726-1733.
14. Tachezy M, Zander H, Marx AH, et al. ALCAM (CD166) expression and serum levels in pancreatic cancer. PLoS One 2012; 7: e39018.
15. Tachezy M, Effenberger K, Zander H, et al. ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients. Int J Cancer 2012; 131: 396-405.
16. Tachezy M, Zander H, Gebauer F, et al. Activated leukocyte cell adhesion molecule (CD166)-Its prognostic power for colorectal cancer patients. J Surg Res 2012; 177: e15-20.
17. Tachezy M, Zander H, Marx AH, et al. ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients. J Surg Res 2011; 170: 226-232.
18. Ishiguro F, Murakami H, Mizuno T, et al. Membranous expression of activated leukocyte cell adhesion molecule contributes to poor prognosis and malignant phenotypes of non-small-cell lung cancer. J Surg Res 2012; 179: 24-32.
19. Simon R, Mirlacher M, Sauter G,. Immunohistochemical analysis of tissue microarrays. Methods Mol Biol 2010; 664: 113-126.
20. Hill RP, Perris R,. "Destemming" cancer stem cells. J Natl Cancer Inst 2007; 99: 1435-1440.
21. Woodward WA, Sulman EP,. Cancer stem cells: Markers or biomarkers? Cancer Metastasis Rev 2008; 27: 459-470.
22. Mollet M, Godoy-Silva R, Berdugo C, et al. Computer simulations of the energy dissipation rate in a fluorescence-activated cell sorter: Implications to cells. Biotechnol Bioeng 2008; 100: 260-272.
23. Meenan J, Obradov DO, van Dullemen H, et al. Use of buffered formaldehyde in the enzymatic digestion of inflamed mucosa. J Clin Pathol 1996; 49: 177-179.
24. Rosso O, Piazza T, Bongarzone I, et al. The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res 2007; 5: 1246-1253.
25. Hansen AG, Freeman TJ, Arnold SA, et al. Elevated ALCAM shedding in colorectal cancer correlates with poor patient outcome. Cancer Res 2013; 73: 2955-2964.
26. Went P, Vasei M, Bubendorf L, et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006; 94: 128-135.
27. Kaifi JT, Reichelt U, Quaas A, et al. L1 is associated with micrometastatic spread and poor outcome in colorectal cancer. Mod Pathol 2007; 20: 1183-1190.
28. Minner S, Kraetzig F, Tachezy M, et al. Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer. Hum Pathol 2011; 42: 1946-1952.
29. Grupp K, Sanader S, Sirma H, et al. High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers. Mol Oncol 2013; 7: 1001-1011.
30. Kalinina T, Gungor C, Thieltges S, et al. Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung. BMC Cancer 2010; 10: 295.
31. Zander H, Rawnaq T, von Wedemeyer M, et al. Circulating levels of cell adhesion molecule L1 as a prognostic marker in gastrointestinal stromal tumor patients. BMC Cancer 2011; 11: 189:181-187.
32. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.